Status:
COMPLETED
Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
2-16 years
Phase:
PHASE3
Brief Summary
This trial is conducted in Europe. The aim of this research is to compare the efficacy and safety of treatment with NPH insulin and insulin detemir. You will be treated with either insulin detemir or...
Eligibility Criteria
Inclusion
- Insulin detemir naive
- Type 1 diabetes for at least 12 months
- HbA1c lesser than or equal to 11.0%
Exclusion
- Significant concomitant diseases
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
348 Patients enrolled
Trial Details
Trial ID
NCT00435019
Start Date
February 1 2007
End Date
September 1 2008
Last Update
March 10 2017
Active Locations (43)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Pleven, Bulgaria, 5800
2
Novo Nordisk Investigational Site
Sofia, Bulgaria, 1606
3
Novo Nordisk Investigational Site
Varna, Bulgaria, 9010
4
Novo Nordisk Investigational Site
Olomouc, Czechia, 77520